STEAP1: a promising target in prostate cancer therapy

Trends Cancer. 2025 Aug;11(8):722-725. doi: 10.1016/j.trecan.2025.05.007. Epub 2025 Jun 16.

Abstract

The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.

Keywords: CAR-T cell; STEAP1; T cell engagers; antibody drug conjugates; immunotherapy; metastatic castration-resistant prostate cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm* / genetics
  • Antigens, Neoplasm* / metabolism
  • Biomarkers, Tumor* / antagonists & inhibitors
  • Biomarkers, Tumor* / genetics
  • Biomarkers, Tumor* / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • Molecular Targeted Therapy / methods
  • Oxidoreductases* / antagonists & inhibitors
  • Oxidoreductases* / genetics
  • Oxidoreductases* / metabolism
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / metabolism
  • Prostatic Neoplasms* / pathology

Substances

  • STEAP1 protein, human
  • Antigens, Neoplasm
  • Oxidoreductases
  • Biomarkers, Tumor